<DOC>
	<DOCNO>NCT00908570</DOCNO>
	<brief_summary>The purpose Phase I study investigate document effect local treatment topical estriol cream vaginal environment pre-menopausal woman .</brief_summary>
	<brief_title>Topical Estriol Vaginal Health</brief_title>
	<detailed_description>There evidence human study estrogen give rise health-promoting change vaginal environment addition affect thickness vaginal epithelium . The purpose propose study take first step test effect local estrogen treatment vaginal health parameter human . We choose estriol product , comparison estrone ( E1 ) estradiol ( E2 ) , estriol ( E3 ) generally consider weak estrogen . The duration estriol 's interaction estrogen receptor quick exhibit rapid metabolic clearance . We choose topical route administration appear result few systemic effect oral administration , allow u concentrate treatment locally area wish affect . Our primary goal test whether topically apply estrogen result significant thickening maturation vaginal epithelium . Our secondary goal measure treatment 's effect parameter vagina , Lactobacillus colonization vaginal pH . If estrogen cream indeed affect vaginal environment pre-menopausal woman post-menopausal woman , study would indicate determine whether estrogen cream vagina decrease risk infection pre-menopausal woman .</detailed_description>
	<criteria>In generally good health Between age 18 40 Report regular , consistent menstrual cycle duration 25 35 day ' duration Agree initiate hormonal contraception systemic vaginal hormonal treatment course study Agree refrain vaginal douching use spermicide , spermicidetreated condom , diaphragm , cervical cap , vaginal hygiene treatment vaginal product course study except explicitly allow study protocol . Not attempt get pregnant ( , sexually active , use allow effective contraceptive i.e. , sterilization male condom ) Has inform health practitioner avoid estrogen treatment Does meet one inclusion criterion Is currently pregnant Is currently lactate Has IUD place Has diabetes control medication Has menstrual bleeding usually exceed 7 day ' duration Has use hormonal contraception systemic vaginal hormonal treatment past three month Has receive systemic antibiotic treatment since start bleed current menstrual period Has know history diagnosis HIV infection Screens positive gonorrhea , Chlamydia , trichomonas Has evidence highgrade dysplasia cervical cancer visual examination Pap smear Has active genital Herpes lesion Has following : Known , past suspect breast cancer ; Known suspect estrogendependent malignant premalignant tumour ( e.g endometrial cancer ) ; History endometrial hyperplasia ; Undiagnosed abnormal genital bleeding ; Previous idiopathic current venous thromboembolism ( deep venous thrombosis , pulmonary embolism ) ; Active recent arterial thromboembolic disease ( e.g . angina , myocardial infarction ) ; Acute liver disease , history liver disease liver function test fail return normal ; Liver disorder adenomas ; Symptomatic gallstone gallbladder disease ( cholecystitis ) ; Hypertriglyceridemia ; Vascular disease associate lupus erythematosus ; Known hypersensitivity estriol ( estrogen E3 ) inactive substance study product ; Porphyria Presents history condition provider , best discretion , feel rule study participation .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>estrogen</keyword>
	<keyword>estriol</keyword>
	<keyword>cream</keyword>
	<keyword>vagina</keyword>
	<keyword>infection prevention</keyword>
</DOC>